Health care stocks were narrowly lower Friday with the NYSE Health Care Sector Index slipping about 0.2% and shares of health care companies in the S&P 500 declining about 0.4% as a group.
Insights about those healthcare sector stocks that gained during Friday’s trade, are depicted underneath:
Second Sight Medical Products Inc (NASDAQ:EYES)’s shares picked up 37.03%, and closed at $16.17, during the last trading session, soon after the news release that a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients, released its 2014 fourth quarter and year-end financial results on Wednesday, March 11, 2015, after the close of the U.S. financial markets.
Second Sight Medical Products Inc (NASDAQ:EYES), was founded in 1998 to create a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations such as retinitis pigmentosa. Second Sight’s mission is to develop, manufacture, and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence.
Sophiris Bio Inc (NASDAQ:SPHS), skyrocketed 63.67%, and closed at $0.802, as a Canada-based biopharmaceutical company, recently declared that Randall E. Woods, president and chief executive officer, presented a corporate overview at the Leerink Global Healthcare Conference. The presentation was on Wednesday, February 11, 2015 at 11:05 a.m. EST in New York City.
Sophiris Bio Inc (NASDAQ:SPHS), is a biopharmaceutical company developing PRX302, a clinical-stage, targeted therapy for the treatment of urological diseases. PRX302 is in Phase 3 clinical development for the treatment of the symptoms of BPH and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments.
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), enhanced 14.86%, and closed at $0.850, soon after the news release that a specialty pharmaceutical company, declared that the Company plans to report financial results for 2014 following the close of financial markets on Monday, March 2, 2015. The Company will host a conference call to talk about the results on Tuesday, March 3, 2015 at 8:30 a.m. ET.
To take part in the live conference call, please dial 888-468-2440 (U.S. and Canada) five to ten minutes preceding to the start of the call. The participant passcode is 7932939.
A replay of the call will be accessible starting March 4, 2015 and ending on March 24, 2015 on the company’s website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 7932939.
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), enhanced 31.72%, and closed at $1.25, soon after the news release that a biopharmaceutical company, declared that administration will host a conference call and webcast on Friday, March 6, 2015, at 8:00 a.m. Eastern Time to talk about the presentation of final results and a predefined biomarker analysis of its BATON-CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer. The presentation, titled “Neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib + mFOLFOX6 as compared to bevacizumab + mFOLFOX6 in metastatic colorectal cancer: post-hoc biomarker analysis of BATON-CRC Phase 2 trial,” will be presented in a poster session on March 6 at the American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization Conference in Orlando, FL.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide improvements in patient outcomes where noteworthy unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that are being leveraged in the clinical development strategy of its therapeutic candidates.
